Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characterization of cerebral tau aggregates with 18F-RO6958948 PET in the ALFA population
2019-004290-84Phase 2Active
- Sponsor
- Barcelonaβeta Brain Research Center
- Start
- May 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18F]RO-948 in Alzheimer's disease (AD), sponsored by Barcelonaβeta Brain Research Center. Primary endpoint: Global and regional retention rate of 18F-RO6958948. Started May 2020; status: active.
02
Drugs
[18F]RO-948
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2019-004290-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004290-84.